OTC Markets OTCQB - Delayed Quote USD
NervGen Pharma Corp. (NGENF)
2.1300
-0.0200
(-0.93%)
At close: April 23 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
24,931.9950
24,931.9950
17,776.7100
23,025.0330
12,811.2240
Operating Income
-24,931.9950
-24,931.9950
-17,776.7100
-23,025.0330
-12,811.2240
Net Non Operating Interest Income Expense
812.6170
812.6170
550.0740
-313.2030
29.4170
Other Income Expense
113.4830
113.4830
-5,155.4840
2,615.9530
55.2290
Pretax Income
-24,005.8950
-24,005.8950
-22,382.1200
-20,722.2830
-12,726.5780
Net Income Common Stockholders
-24,005.8950
-24,005.8950
-22,382.1200
-20,722.2830
-12,726.5780
Diluted NI Available to Com Stockholders
-24,005.8950
-24,005.8950
-22,382.1200
-20,722.2830
-12,726.5780
Basic EPS
-0.38
-0.36
-0.38
-0.39
-0.32
Diluted EPS
-0.38
-0.36
-0.38
-0.39
-0.32
Basic Average Shares
64,715.1500
67,321.6980
59,290.0470
52,649.0350
39,289.2240
Diluted Average Shares
64,715.1500
67,321.6980
59,290.0470
52,649.0350
39,289.2240
Total Expenses
24,931.9950
24,931.9950
17,776.7100
23,025.0330
12,811.2240
Net Income from Continuing & Discontinued Operation
-24,005.8950
-24,005.8950
-22,382.1200
-20,722.2830
-12,726.5780
Normalized Income
-24,119.3780
-24,119.3780
-17,226.6360
-23,338.2360
-12,781.8070
Interest Income
812.6170
812.6170
550.0740
201.3960
29.4170
Interest Expense
--
--
--
514.5990
--
Net Interest Income
812.6170
812.6170
550.0740
-313.2030
29.4170
EBIT
-24,931.9950
-24,931.9950
-17,776.7100
-20,207.6840
-12,726.5780
EBITDA
-24,848.1970
-24,848.1970
-17,631.7080
-20,092.5700
-12,683.9520
Reconciled Depreciation
83.7980
83.7980
145.0020
115.1140
42.6260
Net Income from Continuing Operation Net Minority Interest
-24,005.8950
-24,005.8950
-22,382.1200
-20,722.2830
-12,726.5780
Total Unusual Items Excluding Goodwill
113.4830
113.4830
-5,155.4840
2,615.9530
55.2290
Total Unusual Items
113.4830
113.4830
-5,155.4840
2,615.9530
55.2290
Normalized EBITDA
-24,961.6800
-24,961.6800
-12,476.2240
-22,708.5230
-12,739.1810
12/31/2021 - 4/3/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MDNAF Medicenna Therapeutics Corp.
0.7590
-0.78%
ACXP Acurx Pharmaceuticals, Inc.
0.3870
+2.73%
MSCLF Satellos Bioscience Inc.
0.5020
0.00%
NYMXF Nymox Pharmaceutical Corporation
0.1178
0.00%
RZLT Rezolute, Inc.
3.9700
+27.65%
DRMA Dermata Therapeutics, Inc.
0.7924
+13.20%
BETRF BetterLife Pharma Inc.
0.0680
0.00%
APTOF Aptose Biosciences Inc.
2.3100
-6.48%
ACHV Achieve Life Sciences, Inc.
2.4300
-2.02%
GANX Gain Therapeutics, Inc.
1.8500
0.00%